Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

CancerConnect News The US Food and Drug Administration FDA has granted Fast Track designation for the anti-CTGF antibody pamrevlumab for the treatment of patients with locally advanced unresectable pancreatic cancer This follows review of the Phase 2 clin [...]